AZN - Watch Alexion as FTC says its considering new approach to pharmaceutical deals

The U.S. Federal Trade Commission announced today that it's staring a working group to update its approach to analyzing the effects of pharmaceutical mergers.“Given the high volume of pharmaceutical mergers in recent years, amid skyrocketing drug prices and ongoing concerns about anticompetitive conduct in the industry, it is imperative that we rethink our approach toward pharmaceutical merger review,” said FTC Acting Chair Rebecca Kelly Slaughter said in a statement . “Working hand in hand with international and domestic enforcement partners, we intend to take an aggressive approach to tackling anticompetitive pharmaceutical mergers.”Just yesterday AstraZeneca (AZN) said its planned purchase of Alexion (ALXN) had to be refiled with FTC.Developing story ...

For further details see:

Watch Alexion as FTC says its considering new approach to pharmaceutical deals